566P - Survey of medical oncology status in Korea (SOMOS-K): A national survey of medical oncologists in the Korean Association for Clinical Oncology (KACO)
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Bioethics, Legal, and Economic Issues
|Presenter||Do Yeun Kim|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix184-ix189. 10.1093/annonc/mdw603|
D.Y. Kim1, Y.G. Lee2, B.S. Kim3
The purpose of the SOMOS-K is to investigate the current role of medical oncologists in cancer care and to recognize medical oncology as an independent specialty.
Questionnaires modified from the MOSES (Medical Oncology Status in Europe Survey) were selected that dealt with oncology structure, resources, and patterns of care given by medical oncologists, and research into the field. Several improvements were made to the contents of the questionnaires by feedback from the insurance and policy committee of the KACO. The online survey was sent to full members of the KACO.
In total, 214 medical oncologists (45.8% of the total sent out) answered this survey with seventy one directors of medical oncology of an institution. Most institutions have various resources, such as a department of medical oncology (94.1%) and radiation oncology (82.4%). There was an average of 4 medical oncologists at each institution. Medical oncologists performed their roles across various treatments settings, from diagnosis and end of life care. They contributed as chemotherapy providers with a wide distribution among institutions and types of solid cancers. Clinical research was prominent; 86.2% of institutions conducted some type of research activity.
This first national survey of medical oncology status in Korea demonstrated that medical oncologists play their roles across a wide spectrum of cancer treatment and care. This paper highlights the contributions and proper roles of medical oncologists in the evolving health care environment in Korea.
Clinical trial indentification
Legal entity responsible for the study
Korean Association of Clinical Oncology (KACO)
All authors have declared no conflicts of interest.